Report Detail
Global Recombinant Erythropoietin Drugs Sales Market Report 2021
- RnM3818180 |
- 14 June, 2021 |
- Global |
- 146 Pages |
- QYResearch |
- Pharma & Healthcare
Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. Liver production predominates in the fetal and perinatal period; renal production predominates in adulthood. It is homologous with thrombopoietin.
Market Analysis and Insights: Global Recombinant Erythropoietin Drugs Market
The global Recombinant Erythropoietin Drugs market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.
Global Recombinant Erythropoietin Drugs Scope and Market Size
The global Recombinant Erythropoietin Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Erythropoietin Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)
Segment by Application
Chronic Kidney Disease
Cancer Related Anemia
Others
The Recombinant Erythropoietin Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Recombinant Erythropoietin Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd
1 Recombinant Erythropoietin Drugs Market Overview
- 1.1 Recombinant Erythropoietin Drugs Product Scope
- 1.2 Recombinant Erythropoietin Drugs Segment by Type
- 1.2.1 Global Recombinant Erythropoietin Drugs Sales by Type (2016 & 2021 & 2027)
- 1.2.2 rhEPO
- 1.2.3 Erythropoiesis-Stimulating Agents (ESA)
- 1.3 Recombinant Erythropoietin Drugs Segment by Application
- 1.3.1 Global Recombinant Erythropoietin Drugs Sales Comparison by Application (2016 & 2021 & 2027)
- 1.3.2 Chronic Kidney Disease
- 1.3.3 Cancer Related Anemia
- 1.3.4 Others
- 1.4 Recombinant Erythropoietin Drugs Market Estimates and Forecasts (2016-2027)
- 1.4.1 Global Recombinant Erythropoietin Drugs Market Size in Value Growth Rate (2016-2027)
- 1.4.2 Global Recombinant Erythropoietin Drugs Market Size in Volume Growth Rate (2016-2027)
- 1.4.3 Global Recombinant Erythropoietin Drugs Price Trends (2016-2027)
2 Recombinant Erythropoietin Drugs Estimates and Forecasts by Region
- 2.1 Global Recombinant Erythropoietin Drugs Market Size by Region: 2016 VS 2021 VS 2027
- 2.2 Global Recombinant Erythropoietin Drugs Retrospective Market Scenario by Region (2016-2021)
- 2.2.1 Global Recombinant Erythropoietin Drugs Sales Market Share by Region (2016-2021)
- 2.2.2 Global Recombinant Erythropoietin Drugs Revenue Market Share by Region (2016-2021)
- 2.3 Global Recombinant Erythropoietin Drugs Market Estimates and Forecasts by Region (2022-2027)
- 2.3.1 Global Recombinant Erythropoietin Drugs Sales Estimates and Forecasts by Region (2022-2027)
- 2.3.2 Global Recombinant Erythropoietin Drugs Revenue Forecast by Region (2022-2027)
- 2.4 Geographic Market Analysis: Market Facts & Figures
- 2.4.1 North America Recombinant Erythropoietin Drugs Estimates and Projections (2016-2027)
- 2.4.2 Europe Recombinant Erythropoietin Drugs Estimates and Projections (2016-2027)
- 2.4.3 China Recombinant Erythropoietin Drugs Estimates and Projections (2016-2027)
- 2.4.4 Japan Recombinant Erythropoietin Drugs Estimates and Projections (2016-2027)
- 2.4.5 Southeast Asia Recombinant Erythropoietin Drugs Estimates and Projections (2016-2027)
- 2.4.6 India Recombinant Erythropoietin Drugs Estimates and Projections (2016-2027)
3 Global Recombinant Erythropoietin Drugs Competition Landscape by Players
- 3.1 Global Top Recombinant Erythropoietin Drugs Players by Sales (2016-2021)
- 3.2 Global Top Recombinant Erythropoietin Drugs Players by Revenue (2016-2021)
- 3.3 Global Recombinant Erythropoietin Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Erythropoietin Drugs as of 2020)
- 3.4 Global Recombinant Erythropoietin Drugs Average Price by Company (2016-2021)
- 3.5 Manufacturers Recombinant Erythropoietin Drugs Manufacturing Sites, Area Served, Product Type
- 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Recombinant Erythropoietin Drugs Market Size by Type
- 4.1 Global Recombinant Erythropoietin Drugs Historic Market Review by Type (2016-2021)
- 4.1.1 Global Recombinant Erythropoietin Drugs Sales Market Share by Type (2016-2021)
- 4.1.2 Global Recombinant Erythropoietin Drugs Revenue Market Share by Type (2016-2021)
- 4.1.3 Global Recombinant Erythropoietin Drugs Price by Type (2016-2021)
- 4.2 Global Recombinant Erythropoietin Drugs Market Estimates and Forecasts by Type (2022-2027)
- 4.2.1 Global Recombinant Erythropoietin Drugs Sales Forecast by Type (2022-2027)
- 4.2.2 Global Recombinant Erythropoietin Drugs Revenue Forecast by Type (2022-2027)
- 4.2.3 Global Recombinant Erythropoietin Drugs Price Forecast by Type (2022-2027)
5 Global Recombinant Erythropoietin Drugs Market Size by Application
- 5.1 Global Recombinant Erythropoietin Drugs Historic Market Review by Application (2016-2021)
- 5.1.1 Global Recombinant Erythropoietin Drugs Sales Market Share by Application (2016-2021)
- 5.1.2 Global Recombinant Erythropoietin Drugs Revenue Market Share by Application (2016-2021)
- 5.1.3 Global Recombinant Erythropoietin Drugs Price by Application (2016-2021)
- 5.2 Global Recombinant Erythropoietin Drugs Market Estimates and Forecasts by Application (2022-2027)
- 5.2.1 Global Recombinant Erythropoietin Drugs Sales Forecast by Application (2022-2027)
- 5.2.2 Global Recombinant Erythropoietin Drugs Revenue Forecast by Application (2022-2027)
- 5.2.3 Global Recombinant Erythropoietin Drugs Price Forecast by Application (2022-2027)
6 North America Recombinant Erythropoietin Drugs Market Facts & Figures
- 6.1 North America Recombinant Erythropoietin Drugs Sales by Company
- 6.1.1 North America Recombinant Erythropoietin Drugs Sales by Company (2016-2021)
- 6.1.2 North America Recombinant Erythropoietin Drugs Revenue by Company (2016-2021)
- 6.2 North America Recombinant Erythropoietin Drugs Sales Breakdown by Type
- 6.2.1 North America Recombinant Erythropoietin Drugs Sales Breakdown by Type (2016-2021)
- 6.2.2 North America Recombinant Erythropoietin Drugs Sales Breakdown by Type (2022-2027)
- 6.3 North America Recombinant Erythropoietin Drugs Sales Breakdown by Application
- 6.3.1 North America Recombinant Erythropoietin Drugs Sales Breakdown by Application (2016-2021)
- 6.3.2 North America Recombinant Erythropoietin Drugs Sales Breakdown by Application (2022-2027)
7 Europe Recombinant Erythropoietin Drugs Market Facts & Figures
- 7.1 Europe Recombinant Erythropoietin Drugs Sales by Company
- 7.1.1 Europe Recombinant Erythropoietin Drugs Sales by Company (2016-2021)
- 7.1.2 Europe Recombinant Erythropoietin Drugs Revenue by Company (2016-2021)
- 7.2 Europe Recombinant Erythropoietin Drugs Sales Breakdown by Type
- 7.2.1 Europe Recombinant Erythropoietin Drugs Sales Breakdown by Type (2016-2021)
- 7.2.2 Europe Recombinant Erythropoietin Drugs Sales Breakdown by Type (2022-2027)
- 7.3 Europe Recombinant Erythropoietin Drugs Sales Breakdown by Application
- 7.3.1 Europe 146 Sales Breakdown by Application (2016-2021)
- 7.3.2 Europe 146 Sales Breakdown by Application (2022-2027)
8 China Recombinant Erythropoietin Drugs Market Facts & Figures
- 8.1 China Recombinant Erythropoietin Drugs Sales by Company
- 8.1.1 China Recombinant Erythropoietin Drugs Sales by Company (2016-2021)
- 8.1.2 China Recombinant Erythropoietin Drugs Revenue by Company (2016-2021)
- 8.2 China Recombinant Erythropoietin Drugs Sales Breakdown by Type
- 8.2.1 China Recombinant Erythropoietin Drugs Sales Breakdown by Type (2016-2021)
- 8.2.2 China Recombinant Erythropoietin Drugs Sales Breakdown by Type (2022-2027)
- 8.3 China Recombinant Erythropoietin Drugs Sales Breakdown by Application
- 8.3.1 China 311 Sales Breakdown by Application (2016-2021)
- 8.3.2 China 311 Sales Breakdown by Application (2022-2027)
9 Japan Recombinant Erythropoietin Drugs Market Facts & Figures
- 9.1 Japan Recombinant Erythropoietin Drugs Sales by Company
- 9.1.1 Japan Recombinant Erythropoietin Drugs Sales by Company (2016-2021)
- 9.1.2 Japan Recombinant Erythropoietin Drugs Revenue by Company (2016-2021)
- 9.2 Japan Recombinant Erythropoietin Drugs Sales Breakdown by Type
- 9.2.1 Japan Recombinant Erythropoietin Drugs Sales Breakdown by Type (2016-2021)
- 9.2.2 Japan Recombinant Erythropoietin Drugs Sales Breakdown by Type (2022-2027)
- 9.3 Japan Recombinant Erythropoietin Drugs Sales Breakdown by Application
- 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
- 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Recombinant Erythropoietin Drugs Market Facts & Figures
- 10.1 Southeast Asia Recombinant Erythropoietin Drugs Sales by Company
- 10.1.1 Southeast Asia Recombinant Erythropoietin Drugs Sales by Company (2016-2021)
- 10.1.2 Southeast Asia Recombinant Erythropoietin Drugs Revenue by Company (2016-2021)
- 10.2 Southeast Asia Recombinant Erythropoietin Drugs Sales Breakdown by Type
- 10.2.1 Southeast Asia Recombinant Erythropoietin Drugs Sales Breakdown by Type (2016-2021)
- 10.2.2 Southeast Asia Recombinant Erythropoietin Drugs Sales Breakdown by Type (2022-2027)
- 10.3 Southeast Asia Recombinant Erythropoietin Drugs Sales Breakdown by Application
- 10.3.1 Southeast Asia KG Sales Breakdown by Application (2016-2021)
- 10.3.2 Southeast Asia KG Sales Breakdown by Application (2022-2027)
11 India Recombinant Erythropoietin Drugs Market Facts & Figures
- 11.1 India Recombinant Erythropoietin Drugs Sales by Company
- 11.1.1 India Recombinant Erythropoietin Drugs Sales by Company (2016-2021)
- 11.1.2 India Recombinant Erythropoietin Drugs Revenue by Company (2016-2021)
- 11.2 India Recombinant Erythropoietin Drugs Sales Breakdown by Type
- 11.2.1 India Recombinant Erythropoietin Drugs Sales Breakdown by Type (2016-2021)
- 11.2.2 India Recombinant Erythropoietin Drugs Sales Breakdown by Type (2022-2027)
- 11.3 India Recombinant Erythropoietin Drugs Sales Breakdown by Application
- 11.3.1 India Recombinant Erythropoietin Drugs Sales Breakdown by Application (2016-2021)
- 11.3.2 India Recombinant Erythropoietin Drugs Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Recombinant Erythropoietin Drugs Business
- 12.1 Amgen
- 12.1.1 Amgen Corporation Information
- 12.1.2 Amgen Business Overview
- 12.1.3 Amgen Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.1.4 Amgen Recombinant Erythropoietin Drugs Products Offered
- 12.1.5 Amgen Recent Development
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Corporation Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.2.4 Johnson & Johnson Recombinant Erythropoietin Drugs Products Offered
- 12.2.5 Johnson & Johnson Recent Development
- 12.3 Kyowa Hakko Kirin
- 12.3.1 Kyowa Hakko Kirin Corporation Information
- 12.3.2 Kyowa Hakko Kirin Business Overview
- 12.3.3 Kyowa Hakko Kirin Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.3.4 Kyowa Hakko Kirin Recombinant Erythropoietin Drugs Products Offered
- 12.3.5 Kyowa Hakko Kirin Recent Development
- 12.4 Roche
- 12.4.1 Roche Corporation Information
- 12.4.2 Roche Business Overview
- 12.4.3 Roche Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.4.4 Roche Recombinant Erythropoietin Drugs Products Offered
- 12.4.5 Roche Recent Development
- 12.5 3SBio Group
- 12.5.1 3SBio Group Corporation Information
- 12.5.2 3SBio Group Business Overview
- 12.5.3 3SBio Group Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.5.4 3SBio Group Recombinant Erythropoietin Drugs Products Offered
- 12.5.5 3SBio Group Recent Development
- 12.6 Celltrion, Inc
- 12.6.1 Celltrion, Inc Corporation Information
- 12.6.2 Celltrion, Inc Business Overview
- 12.6.3 Celltrion, Inc Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.6.4 Celltrion, Inc Recombinant Erythropoietin Drugs Products Offered
- 12.6.5 Celltrion, Inc Recent Development
- 12.7 Teva Pharmaceutical Industries Ltd
- 12.7.1 Teva Pharmaceutical Industries Ltd Corporation Information
- 12.7.2 Teva Pharmaceutical Industries Ltd Business Overview
- 12.7.3 Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.7.4 Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Products Offered
- 12.7.5 Teva Pharmaceutical Industries Ltd Recent Development
- 12.8 F. Hoffmann-La Roche Ltd
- 12.8.1 F. Hoffmann-La Roche Ltd Corporation Information
- 12.8.2 F. Hoffmann-La Roche Ltd Business Overview
- 12.8.3 F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.8.4 F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Drugs Products Offered
- 12.8.5 F. Hoffmann-La Roche Ltd Recent Development
- 12.9 LG Life Sciences Ltd
- 12.9.1 LG Life Sciences Ltd Corporation Information
- 12.9.2 LG Life Sciences Ltd Business Overview
- 12.9.3 LG Life Sciences Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.9.4 LG Life Sciences Ltd Recombinant Erythropoietin Drugs Products Offered
- 12.9.5 LG Life Sciences Ltd Recent Development
- 12.10 Biocon Limited
- 12.10.1 Biocon Limited Corporation Information
- 12.10.2 Biocon Limited Business Overview
- 12.10.3 Biocon Limited Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.10.4 Biocon Limited Recombinant Erythropoietin Drugs Products Offered
- 12.10.5 Biocon Limited Recent Development
- 12.11 Intas Pharmaceuticals Ltd
- 12.11.1 Intas Pharmaceuticals Ltd Corporation Information
- 12.11.2 Intas Pharmaceuticals Ltd Business Overview
- 12.11.3 Intas Pharmaceuticals Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.11.4 Intas Pharmaceuticals Ltd Recombinant Erythropoietin Drugs Products Offered
- 12.11.5 Intas Pharmaceuticals Ltd Recent Development
- 12.12 Sun Pharmaceutical Industries Ltd
- 12.12.1 Sun Pharmaceutical Industries Ltd Corporation Information
- 12.12.2 Sun Pharmaceutical Industries Ltd Business Overview
- 12.12.3 Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.12.4 Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Products Offered
- 12.12.5 Sun Pharmaceutical Industries Ltd Recent Development
- 12.13 Dr. Reddy's Laboratories Ltd
- 12.13.1 Dr. Reddy's Laboratories Ltd Corporation Information
- 12.13.2 Dr. Reddy's Laboratories Ltd Business Overview
- 12.13.3 Dr. Reddy's Laboratories Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2016-2021)
- 12.13.4 Dr. Reddy's Laboratories Ltd Recombinant Erythropoietin Drugs Products Offered
- 12.13.5 Dr. Reddy's Laboratories Ltd Recent Development
13 Recombinant Erythropoietin Drugs Manufacturing Cost Analysis
- 13.1 Recombinant Erythropoietin Drugs Key Raw Materials Analysis
- 13.1.1 Key Raw Materials
- 13.1.2 Key Raw Materials Price Trend
- 13.1.3 Key Suppliers of Raw Materials
- 13.2 Proportion of Manufacturing Cost Structure
- 13.3 Manufacturing Process Analysis of Recombinant Erythropoietin Drugs
- 13.4 Recombinant Erythropoietin Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
- 14.1 Marketing Channel
- 14.2 Recombinant Erythropoietin Drugs Distributors List
- 14.3 Recombinant Erythropoietin Drugs Customers
15 Market Dynamics
- 15.1 Recombinant Erythropoietin Drugs Market Trends
- 15.2 Recombinant Erythropoietin Drugs Drivers
- 15.3 Recombinant Erythropoietin Drugs Market Challenges
- 15.4 Recombinant Erythropoietin Drugs Market Restraints
16 Research Findings and Conclusion
17 Appendix
- 17.1 Research Methodology
- 17.1.1 Methodology/Research Approach
- 17.1.2 Data Source
- 17.2 Author List
Summary:
Get latest Market Research Reports on Recombinant Erythropoietin Drugs. Industry analysis & Market Report on Recombinant Erythropoietin Drugs is a syndicated market report, published as Global Recombinant Erythropoietin Drugs Sales Market Report 2021. It is complete Research Study and Industry Analysis of Recombinant Erythropoietin Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
